IMATINIB CRISTERS 100 mg, film-coated tablet scored 60 tablets
Active ingredients: Imatinib, Imatinib mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet scored60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IMATINIB CRISTERS 100 mg, comprimé pelliculé sécable
- Pharmaceutical form
- comprimé pelliculé sécable
- Route of administration
- orale
- Presentation description
- plaquette(s) aluminium de 60 comprimé(s)
- Marketing authorisation holder
- CRISTERS
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Jun 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65074589CIP73009683CIP133400930096833Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IMATINIBcomprimé | 100 mg · un comprimé | FT |
| MÉSILATE D'IMATINIBcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.